JAMA NetworkAssessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients w. Neuroendocrine Tumors: A Nonrandomized Clinical Trial

Following treatment of the 40 study patients with bevacizumab and atezolizumab, OS was observed in 4 patients with pNETs (20%) and 3 patients with epNETs (15%). The PFS was 14.9 months and 14.2 months in these cohorts, respectively. The findings suggest that clinical responses in patients with NET may follow treatment with the combination of bevacizumab and atezolizumab, with a PFS consistent with effective therapies.